Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials-Reference-Cited by-同舟云学术

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

Published:2016-08-23 Issue:11 Volume:63 Page:1479-1481
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:Clin Infect Dis.

Author:

Grebely Jason,Dore Gregory J.,Zeuzem Stefan,Aspinall Richard J.,Fox Raymond,Han Lingling,McNally John,Osinusi Anu,Brainard Diana M.,Subramanian G. Mani,Natha Macky,Foster Graham R.,Mangia Alessandra,Sulkowski Mark,Feld Jordan J.

Funder

National Institutes of Health

National Institute on Drug Abuse

Gilead Sciences

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference12 articles.

1. Epidemiology and natural history of HCV infection

2. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

3. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

4. AASLD /IDSA. Recommendations for testing, managing, and treating hepatitis C. In; 2015. Available at: www.hcvguidelines.org/. Accessed 1 September 2016.

5. Recommendations for the management of hepatitis C virus infection among people who inject drugs

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GRAND PLAN: Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of Hepatitis C Virus Infection Among People Initially Disengaged From Health Care Who Use Drugs—A Systematic Multidisciplinary Approach;Open Forum Infectious Diseases;2024-02-29

2. Real‐world hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics in Ontario, Canada;Journal of Viral Hepatitis;2024-02-22

3. Evaluation of Hepatitis C Treatment Outcomes Among Patients Enrolled in Outpatient Parenteral Antibiotic Therapy—Boston, Massachusetts, 2016–2021;Open Forum Infectious Diseases;2023-07-01

4. Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya;International Journal of Drug Policy;2023-03

5. Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment;Clinical Infectious Diseases;2023-01-24